-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 5, J. Capital Research, a capital research firm, released a report saying that Baiji state may have "faked" sales. The report lists seven suspects, including capital expenditure, excessive research and development spending, false income, no privileges, suspicious acquisitions, no investment value, and falsified sales, as suspected of falsifying nearly 60 percent of sales and falsifying more than $154 million in revenue.According to relevant data, Baiji Shenzhou is the first Chinese innovative biopharmaceutical company to go public in the United States and hong Kong, China, at the same time, has not yet achieved profitability.
Today, Baiji Shenzhou issued a clarification notice that said: This is an unfounded and misleading allegations of the report, aimed at negatively affecting Baiji Shenzhou's share price, in order to satisfy the private interests of short-selling institutions. The allegations in the report are blatantly false.Baiji Shenzhou also confirmed that Baiji Shenzhou does not currently have any inside information to be published under Section 13.09 of the Securities Listing Rules of the Stock Exchange of Hong Kong Limited and Section 571 of the Securities and Futures Ordinance XIVA Department.Notably, Baiji Shenzhou has not responded to seven questions in the short report of J.Capital Research, a capital research firm. (Sina Pharmaceutical News)
